Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageWe are a leading digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Our principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that we believe allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Business segments
Q2 2026 · $224.2MThe company’s own SEC segment disclosure.
- Commercial Payors$113.8M51%
- Centers For Medicare Medicaid Services$58.5M26%
- Healthcare Institutions$37.8M17%
- Non Contracted Third Party Payors$14.1M6%
iRhythm Holdings, Inc. (IRTC) reported revenue of $224M in Q2 2026 (quarter ended Jun 30, 2026), up 20% from the same quarter a year earlier. That came with a gross margin of 73% and net loss of $381K. For the full year FY2025, revenue was $747M (+26% year on year) and net income −$45M. Its largest product in Q2 2026 was Commercial Payors at $114M, 51% of the disclosed total, well ahead of Centers For Medicare Medicaid Services at 26%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.